AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26303326
Drug: Standard 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 40 Hz stimulation therapy
Trial: 21600592
Drug: 2-dose methylprednisolone
RxNorm normalized name: methylprednisolone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose methylprednisolone (30 mg/kg per dose, 8 hours preoperatively and operatively)
Trial: 21600592
Drug: Single-dose methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose methylprednisolone (30 mg/kg per dose, operatively)
Trial: 19249999
Drug: RES-C (Resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RES-C (Resistance Training + Chiropractic Treatment)
Trial: 16977477
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine patch (3.5 mg/day during weeks 1 and 4; 7 mg/day during weeks 2 and 3)
Trial: 15267123
Drug: Alendronate 10
RxNorm normalized name: ALENDRONATE 10MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 10 mg/daily (1000 patients)
Trial: 15267123
Drug: Clodronate 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 100 mg/weekly i.m. (800 patients)
Trial: 15267123
Drug: Risedronate 5
RxNorm normalized name: risedronate 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 5 mg/daily (100 patients)
Trial: 15267123
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg/daily (100 patients)
Trial: 11300446
Drug: Cerivastatin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin (0.4 mg/d)
Trial: 9258982
Drug: Oxybutynin 10
RxNorm normalized name: oxyBUTYnin 10% transdermal gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin 10 mg controlled-release tablet ingested 2 hr after breakfast
Trial: 9258982
Drug: Oxybutynin 10
RxNorm normalized name: oxyBUTYnin 10% transdermal gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin 10 mg controlled-release tablet ingested during fasting
Trial: 9258982
Drug: Oxybutynin 10
RxNorm normalized name: oxyBUTYnin 10% transdermal gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin 10 mg controlled-release tablet ingested 1 hr before breakfast
Trial: 27492018
Drug: K2 tablet
RxNorm normalized name: vitamin K2 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K2 tablet (12.4% w/w Kollidon(®) SR)
Trial: 27492018
Drug: Immediate-release tablet
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release tablet (R)
Trial: 11777120
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (PSCT and BMT/PSCT)
Trial: 8410398
Drug: Treatment associated
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment associated with higher mortality
Trial: 8410398
Drug: Treatment associated
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment associated with lower mortality
Trial: 3104218
Drug: HB420 (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB420 (3.5 mg/tablet)
Trial: 3104218
Drug: HB419 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB419 (5 mg/tablet)
Trial: 28317094
Drug: Dexamethasone 1
RxNorm normalized name: dexamethasone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 1 mg.kg‐1
Trial: 25566694
Drug: Transfusion threshold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion threshold <7 g/dl
Trial: 25566694
Drug: Transfusion threshold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion threshold 10 g/dl
Trial: 15177955
Drug: Intraoperative mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative mitomycin C (0.5 mg/ml for 5 minutes)
Trial: 11224634
Drug: Calcium heparin
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparin 5,000 units every 8 hours
Trial: 11224634
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg once daily (plus two additional saline injections)
Trial: 7899804
Drug: Arteflene (Ro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arteflene (Ro 42-1611) 300 mg or higher doses
Trial: 7899804
Drug: Arteflene (Ro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arteflene (Ro 42-1611) 100, 300, 900, 1800, 2700, and 3600 mg
Trial: 31209720
Drug: Sterilized probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterilized probiotic with 5.85 g polydextrose daily for 1 week (Group A)
Trial: 31209720
Drug: Sterilized probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterilized probiotic without polydextrose daily for 1 week (Group B)
Trial: 29526580
Drug: Home particle
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home particle repositioning maneuver (PRM) once weekly for five years
Trial: 26607646
Drug: 80 kVp,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 kVp, 600 mAs, 35 ml CM at an injection rate of 3.5-4.5 ml/s
Trial: 26607646
Drug: 100 kVp,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 kVp, 600 mAs, 70 ml CM at an injection rate of 4.5-5.5 ml/s
Trial: 20361904
Drug: Divalproex sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex sodium extended-release (ER) at a daily dosage initiated at 20 mg/kg for 21 days
Trial: 10577853
Drug: Chemotherapy (mitomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (mitomycin 20 mg/m² IV on day 1, followed by tegafur 400 mg bid daily for 3 months)
Trial: 29961161
Drug: Sirukumab 25
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 25 mg every 4 weeks (q4w)
Trial: 29961161
Drug: Sirukumab 50
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 50 mg every 4 weeks (q4w)
Trial: 29961161
Drug: Sirukumab 100
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 100 mg every 4 weeks (q4w)
Trial: 24699939
Drug: Sirukumab 100
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 100 mg every 2 weeks (q2w)
Trial: 21956255
Drug: Micafungin 50
RxNorm normalized name: micafungin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin 50 mg/day
Trial: 21956255
Drug: Micafungin 150
RxNorm normalized name: micafungin 150 MG in 150 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin 150 mg/day
Trial: 21956255
Drug: Micafungin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin (all doses)
Trial: 16241027
Drug: No antiseptic
RxNorm normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiseptic agent
Trial: 12914870
Drug: Metoprolol 50
RxNorm normalized name: metoprolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 50 mg or carvedilol 25 mg twice daily after a 4-week dose titration period
Trial: 10340366
Drug: Tremacamra (367
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremacamra (367 microg per nostril per dose, total of 4.4 mg/d)
Trial: 7546157
Drug: CyA‐NOF (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyA‐NOF (7.5 mg/kg)
Trial: 31709738
Drug: Gliclazide modified
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide modified release 120 mg
Trial: 30193295
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy (FEC followed by paclitaxel and trastuzumab)
Trial: 30193295
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy (Paclitaxel and trastuzumab followed by FEC and trastuzumab)
Trial: 29240863
Drug: Efinaconazole 10%
RxNorm normalized name: EFINACONAZOLE 10% SOLN,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efinaconazole 10% topical solution, once-daily for 48 weeks, with two 12-week post-treatment follow-ups (at week 60 and 72)
Trial: 29240863
Drug: Efinaconazole 10%
RxNorm normalized name: EFINACONAZOLE 10% SOLN,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efinaconazole 10% topical solution, once-daily for 48 weeks
Trial: 15157254
Drug: Biotinylated RBCs
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biotinylated RBCs plus unlabeled allogeneic RBCs (1.0 mL of biotinylated RBCs plus 15 mL per kg of unlabeled allogeneic RBCs)
Trial: 2072515
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural administration of 1% mepivacaine at a rate of 2 ml.hr‐1
Trial: 2072515
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus administration of 1% mepivacaine 4-5 times daily
Trial: 2072515
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy including infusion of Ringer's solution and diuretics (Control group)
Trial: 6653649
Drug: Penbutolol (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol (i.v. doses of 3, 6, and 12 mg)
Trial: 6653649
Drug: Penbutolol (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol (i.v. doses)
Trial: 6653649
Drug: Penbutolol (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol (oral doses of 40, 80, and 120 mg)
Trial: 6653649
Drug: Penbutolol (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol (oral doses)
Trial: 6653649
Drug: Penbutolol (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol (i.v. administration)
Trial: 6653649
Drug: Penbutolol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol (all doses)
Trial: 28323806
Drug: Standard pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pain management plus perioperative nonsteroidal anti-inflammatory drugs
Trial: 22035157
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg twice weekly (BIW)
Trial: 17894653
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg bisacodyl with 2-L sulphate-free electrolyte lavage
Trial: 17894653
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg bisacodyl with 2-L sulphate-free electrolyte lavage
Trial: 14978550
Drug: Zinc chelate
RxNorm normalized name: glycine zinc chelate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc chelate 1 mg/kg daily for 3 months
Trial: 11915705
Drug: Intraosseous infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraosseous infusion technique
Trial: 11915705
Drug: Traditional drugs
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional drugs
Trial: 8085688
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g orally every 6 hours)
Trial: 8085688
Drug: Cimetidine (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (continuous intravenous, titrated to maintain gastric pH at 4.0)
Trial: 19712155
Drug: Deltamethrin suspension
RxNorm normalized name: decamethrin
DrugBank: Deltamethrin (DB13600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deltamethrin suspension concentrate (SC)
Trial: 17043157
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II (2 ng/kg per minute) during spironolactone (50 mg per day)
Trial: 10675427
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (20 ppm for 24 hours, then 5 ppm for 96 hours)
Trial: 31563977
Drug: Peritonsillar infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritonsillar infiltration with 1 mg/kg bupivacaine (0.5%) totaling 5 mL
Trial: 31563977
Drug: Glossotonsillar sulcus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glossotonsillar sulcus infiltration with 1 mg/kg bupivacaine (0.5%) totaling 5 mL
Trial: 30053199
Drug: Treatment according
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment according to a pre-defined algorithm in a tight control regimen
Trial: 27513278
Drug: Sirolimus therapy
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus therapy for 2 years at doses adjusted to maintain a trough blood level of 5-15 ng/ml
Trial: 26702788
Drug: Conventional Cigarette
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Cigarette (CC)
Trial: 18803446
Drug: Memantine and
RxNorm normalized name: donepezil, memantine and Ginkgo folium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine and donepezil (individually or in combination)
Trial: 12182748
Drug: ABT-229 5
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-229 5 mg b.d.
Trial: 12182748
Drug: ABT-229 10
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-229 10 mg b.d.
Trial: 12182748
Drug: ABT-229 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-229 2.5 mg b.d.
Trial: 12182748
Drug: ABT-229 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-229 (all doses)
Trial: 10350664
Drug: Cerivastatin (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin (0.05 to 0.3 mg/day)
Trial: 10350664
Drug: Simvastatin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (5 to 40 mg/day)
Trial: 7703043
Drug: Doxorubicin (270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (270 to 300 mg/m2 cumulative dose)
Trial: 1838289
Drug: Control (similar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (similar treatment without magnesium)
Trial: 30382824
Drug: RTX plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTX plus MMF (1000-1200 mg/m2/day, maximum 2 g/day, twice daily for 17 months)
Trial: 20565725
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg oral salmon calcitonin (sCT)
Trial: 20565725
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg oral salmon calcitonin (sCT)
Trial: 17384931
Drug: Extended daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended daily dialysis with filtration (EDDf)
Trial: 14607735
Drug: TACE+MLT (melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE+MLT (melatonin 20 mg/d orally, 7 days before TACE)
Trial: 7485886
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml isobaric 0.5% bupivacaine intrathecally without aspirating cerebrospinal fluid
Trial: 7485886
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml isobaric 0.5% bupivacaine mixed with 1 ml cerebrospinal fluid (total 4 ml)
Trial: 7485886
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml isobaric 0.5% bupivacaine mixed with 2 ml cerebrospinal fluid (total 5 ml)
Trial: 2258790
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 160 mg verapamil with 25 mg hydrochlorothiazide and 50 mg triameterene
Trial: 7218018
Drug: 30 cc
RxNorm normalized name: TITANIUM DIOXIDE 2.5 mg in 100 mg / ZINC OXIDE 7.2 mg in 100 mg TOPICAL CREAM [Arbonne Intelligence Pollution Defense SPF30 CC Cream - Light Shade]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 cc of milk of magnesia plus 5 cc of cascara
Trial: 29425477
Drug: Sumac capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumac capsules (500 mg/twice daily)
Trial: 22085227
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy plus tadalafil 5 mg once daily for 4 weeks
Trial: 22085227
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy alone for 4 weeks
Trial: 17593233
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion (CSII) with a short‐acting insulin analogue, 2 IU/h, for 8 h during three consecutive nights (period A)
Trial: 17593233
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion (CSII) with a short‐acting insulin analogue, 2 IU/h, for 8 h during three consecutive nights (period B and C)
Trial: 12519875
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of GH treatment (3 IU/m2 x d)
Trial: 12519875
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of GH treatment (6 IU/m2 x d)
Trial: 12519875
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of GH treatment (both dosage groups)
Trial: 9169959
Drug: Nefazodone 200
RxNorm normalized name: NEFAZODONE 200MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone 200 mg daily for 1 week, followed by 400 mg daily for 7 weeks
Trial: 20710020
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg kg(‐1) bolus dose followed by a 5‐20‐40‐120 min, 10‐8‐6‐5 mg kg(‐1) h(‐1) infusion.
Trial: 16171718
Drug: No hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No hormone replacement (n = 9)
Trial: 12767571
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) 150 mg administered orally on days 5 through 9 of the CC-induced cycle
Trial: 10489026
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a 22 microg weekly
Trial: 10489026
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a 44 microg weekly
Trial: 1881695
Drug: Amoxicillin +
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin + Metronidazole
Trial: 26999243
Drug: sLPD (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sLPD (0.6 g/kg/d with 0.09 g/kg/d keto acids)
Trial: 26999243
Drug: NPD (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPD (1.0 g/kg/d)
Trial: 24534120
Drug: CT-guided fiducial
RxNorm normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-guided fiducial seed placement with concurrent biopsy
Trial: 22186223
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with potassium bromide (1 g, tid) and methimazole (10 mg, tid)
Trial: 22186223
Drug: Methimazole only
RxNorm normalized name: Methimazole only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole only (10 mg, tid) with starch placebo (1 g, tid)
Trial: 20397591
Drug: Suspicion as
RxNorm normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspicion as a receptor's personal disposition
Trial: 12721780
Drug: Alcohol (0.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.25, 0.50, 0.75 g/kg based on total body water)
Trial: 12721780
Drug: No alcohol
RxNorm normalized name: BENZALKONIUM CHLORIDE 0.13 g in 100 mL TOPICAL SOLUTION [Zoono Alcohol Free Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No alcohol administration
Trial: 10226770
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) administered orally to 24 patients
Trial: 10226770
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group of 21 patients without pentoxifylline administration
Trial: 8679274
Drug: Vitamin supplementation
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin supplementation with beta-carotene (30 mg/d) and alpha-tocopherol (400 IU/d)
Trial: 6413133
Drug: Branched chain
RxNorm normalized name: Branched Chain Amino Acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched chain amino acid (BcAA) enriched parenteral nutrition at doses of 0.16, 0.3, 0.5, and 0.7 g/kg . day